Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 3/20 | 0.53 |
| ▸ | PTPRCAP | Q14761 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174699 | 0.81 | HTR2C (0.68) | HTR2CHTR2AHTR2BDRD3DRD1 | |
| SCHEMBL6237859 | 0.81 | HTR2C (0.70) | HTR2CHTR2AHTR2BDRD3DRD1 | |
| SCHEMBL1345733 | 0.79 | HTR1A (0.63) | HTR2CHTR2AHTR2BDRD3DRD1 | |
| SCHEMBL3160390 | 0.77 | HTR2C (0.65) | HTR2CHTR2AHTR2BDRD3DRD1 | |
| SCHEMBL1345825 | 0.75 | HTR2C (0.62) | HTR2CHTR2AHTR2BDRD3DRD1 | |
| SCHEMBL3178138 | 0.74 | HTR2C (0.58) | HTR2CHTR2AHTR2BDRD3DRD1 | |
| Bromide SCHEMBL6905306 | 0.74 | HTR2C (0.61) | HTR2CHTR2AHTR2BDRD3DRD1 | |
| SCHEMBL14782159 | 0.72 | HTR2C (0.58) | HTR2CHTR2AHTR2BDRD3DRD1 | |
| Bromide SCHEMBL7111710 | 0.71 | HTR2C (0.57) | HTR2CHTR2AHTR2BDRD3DRD1 | |
| SCHEMBL22960779 | 0.70 | DRD2 (0.70) | HTR2CHTR2AHTR2BDRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7648995-B2 | R(—)-11-hydroxyaporphine derivatives and uses thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-01-19 | — | — | US | disclosed |
| US-20060040900-A1 | R(-)-11-hydroxyaporphine derivatives and uses thereof | MCLEAN HOSPITAL CORPORATION, THE | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040900-A1 | R(-)-11-hydroxyaporphine derivatives and uses thereof | SNCA, HTR5A, PARK7 | HTR2C 10/4885HTR2A 7/4885HTR2B 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.